Eli Lilly Launches Second Education Program for Medical Students
Eli Lilly and Company has launch of another medical student education program, an internship for aspiring physicians. The Lilly Medical Student Intern Program, the second phase of its medical student programs, offers opportunities for medical students between their first and second years to work alongside healthcare professionals in the pharmaceutical industry to gain scientific knowledge and experience in several areas, including preclinical research, clinical trial development, medical affairs, regulatory affairs, bio-ethics and patient safety.
Six students from Marian University College of Osteopathic Medicine will be the first to participate in the intern program at Eli Lilly and Company's Indianapolis headquarters. Students will expand their knowledge of the industry by spending time at other facilities, including Covance and Elanco, networking with executive leadership and participating in team-building activities with other summer interns across the company.
"We see a great synergy in the making, as these students will have the opportunity to obtain unique, real-world experiences in the realm of drug discovery and development and the myriad of regulatory, legal and business aspects of the pharmaceutical industry," said Dr Bryan Larsen, PhD, associate dean for biomedical sciences, Marian University College of Osteopathic Medicine. "And Marian University will enjoy an unprecedented opportunity to showcase some of its very promising student doctors to the leaders of one of the most revered pharmaceutical companies in the world," he added.
This is the second medical student program launched by Lilly this year. In February, Lilly announced a new partnership with Tulane University School of Medicine to debut the Medical Student Rotation Program, a 4-week experiential learning program for fourth-year medical students.
The 10-week internship program with Marian University students, which will run from May through August, matches interns with projects based on their skills and interests. Experienced, knowledgeable mentors will help students gain hands-on experience and explore diverse career options in healthcare.
"By participating in this program, students will gain experience in drug development, interact with professionals in a variety of medical roles, and further develop leadership skills," said Katie Sugarman, MD, Senior Director, Global Regulatory Affairs — Oncology, Eli Lilly and Company, and a Lilly mentor in the new medical student programs. "We believe this internship will provide students with a better understanding of how physicians contribute to patient outcomes in this area of healthcare."
Both the Intern Program and Medical Student Rotation Program highlight Lilly's ongoing commitment to medical education.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.